Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 10241
Country/Region: Zambia
Year: 2016
Main Partner: Catholic Relief Services
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $0 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_DSD Age/sex: <1 2017 30
HTC_TST_DSD Age/sex: 1-9 2017 40
HTC_TST_DSD Age/sex: 10-14 Female 2017 9
HTC_TST_DSD Age/sex: 10-14 Male 2017 9
HTC_TST_DSD Age/sex: 15-19 Female 2017 52
HTC_TST_DSD Age/sex: 15-19 Male 2017 28
HTC_TST_DSD Age/sex: 20-24 Female 2017 180
HTC_TST_DSD Age/sex: 20-24 Male 2017 96
HTC_TST_DSD Age/sex: 25-49 Female 2017 232
HTC_TST_DSD Age/sex: 25-49 Male 2017 126
HTC_TST_DSD Age/sex: 50+ Female 2017 52
HTC_TST_DSD Age/sex: 50+ Male 2017 28
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 44
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 44
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 476
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 318
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 882
HTC_TST_DSD Service Delivery Point (Facility): Index testing 2017 20
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 88
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 69
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 132
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 88
HTC_TST_DSD Service Delivery Point (Facility): TB Clinics 2017 44
HTC_TST_DSD Service Delivery Point (Facility): VCT 2017 441
HTC_TST_DSD Sum of Age/Sex disaggregates 2017 812
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 88
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 794
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 882
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 2017 1
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 2017 1
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 2017 5
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 2017 3
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Female 2017 18
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 2017 10
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Female 2017 22
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 2017 12
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Female 2017 5
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 2017 3
HTC_TST_DSD Test Result by Age: Positive: <1 2017 4
HTC_TST_DSD Test Result by Age: Positive: 1-9 2017 4
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 4
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 4
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 48
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 32
PP_PREV_DSD Aggregated Age/sex: <15 Female 2017 18
PP_PREV_DSD Aggregated Age/sex: <15 Male 2017 17
PP_PREV_DSD Aggregated Age/sex: 15+ Female 2017 204
PP_PREV_DSD Aggregated Age/sex: 15+ Male 2017 110
PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 349
PP_PREV_DSD Total number of people in the target population 2017 349
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 11
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 6
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 19
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 19
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,191
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 60
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 834
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 297
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 1,191
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 2,787
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 1,500
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 238
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 238
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 4,763
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 67
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 52
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 133
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 133
TX_CURR_DSD Age/Sex: <1 2017 50
TX_CURR_DSD Age/Sex: <1-9 2017 64
TX_CURR_DSD Age/Sex: 10-14 Female 2017 14
TX_CURR_DSD Age/Sex: 10-14 Male 2017 14
TX_CURR_DSD Age/Sex: 15-19 Female 2017 83
TX_CURR_DSD Age/Sex: 15-19 Male 2017 45
TX_CURR_DSD Age/Sex: 20-24 Female 2017 290
TX_CURR_DSD Age/Sex: 20-24 Male 2017 156
TX_CURR_DSD Age/Sex: 25-49 Female 2017 373
TX_CURR_DSD Age/Sex: 25-49 Male 2017 200
TX_CURR_DSD Age/Sex: 50+ Female 2017 83
TX_CURR_DSD Age/Sex: 50+ Male 2017 45
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 71
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 71
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 765
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 510
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 1,417
TX_CURR_DSD Sum of age/sex disaggregates 2017 128
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 142
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 1,275
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 1,417
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 17
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 17
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 178
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 120
TX_NEW_DSD By Age/Sex: <1 2017 12
TX_NEW_DSD By Age/Sex: 1-9 2017 15
TX_NEW_DSD By Age/Sex: 10-14 Female 2017 3
TX_NEW_DSD By Age/Sex: 10-14 Male 2017 3
TX_NEW_DSD By Age/Sex: 15-19 Female 2017 19
TX_NEW_DSD By Age/Sex: 15-19 Male 2017 10
TX_NEW_DSD By Age/Sex: 20-24 Female 2017 68
TX_NEW_DSD By Age/Sex: 20-24 Male 2017 37
TX_NEW_DSD By Age/Sex: 25-49 Female 2017 88
TX_NEW_DSD By Age/Sex: 25-49 Male 2017 48
TX_NEW_DSD By Age/Sex: 50+ Female 2017 19
TX_NEW_DSD By Age/Sex: 50+ Male 2017 10
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 332
TX_NEW_DSD Sum of Age/Sex disaggregates 2017 305
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 332
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 27
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 27
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 318
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 171
TX_PVLS_DSD Denominator: Indication: Routine 2017 489
TX_PVLS_DSD Denominator: Indication: Targeted 2017 54
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 543
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 543
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 27
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 27
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 318
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 171
TX_PVLS_DSD Numerator: Indication: Routine 2017 489
TX_PVLS_DSD Numerator: Indication: Targeted 2017 54
TX_RET_DSD Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11
TX_RET_DSD Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 11
TX_RET_DSD Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 25
TX_RET_DSD Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 25
TX_RET_DSD Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12
TX_RET_DSD Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12
TX_RET_DSD Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12
TX_RET_DSD Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12
TX_RET_DSD Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 53
TX_RET_DSD Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 53
TX_RET_DSD Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 24
TX_RET_DSD Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 24
TX_RET_DSD Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 106
TX_RET_DSD Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 106
TX_RET_DSD Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 46
TX_RET_DSD Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 46
TX_RET_DSD Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 133
TX_RET_DSD Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 133
TX_RET_DSD Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 120
TX_RET_DSD Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 120
TX_RET_DSD Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 27
TX_RET_DSD Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 27
TX_RET_DSD Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20
TX_RET_DSD Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 20
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 345
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 345
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 186
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 186
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 589
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 589